Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders—Crohn’s disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, inflixi...

Descripción completa

Detalles Bibliográficos
Autores principales: Petric, Zvonimir, Goncalves, Joao, Paixao, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505802/
https://www.ncbi.nlm.nih.gov/pubmed/36145514
http://dx.doi.org/10.3390/pharmaceutics14091766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505802/
https://www.ncbi.nlm.nih.gov/pubmed/36145514
http://dx.doi.org/10.3390/pharmaceutics14091766

Ejemplares similares